Links Home FDA Information

Aromasin This page contains recent news articles, when available, and an overview of Aromasin (exemestane)Recent news articles mentioning Aromasin Further Evidence Supporting a Switch to Aromasin® Following Two to ...  -  Feb 16, 2007 Cancer Consultants (press release), One group of patients continued to receive Nolvadex for five years, while the other group switched to Aromasin for the remainder of the five-year treatment Study Published in British Medical Journal The Lancet Shows ...  -  Feb 15, 2007 Drug Newswire (press release), Aromasin, a third-generation aromatase inhibitor, is the only anti- hormonal therapy in a single trial shown to indicate improved overall survival over Study Published In British Medical Journal The Lancet Shows ...  -  Feb 14, 2007 Medical News Today (press release), Research from the Intergroup Exemestane Study (IES) published today in The Lancet shows for the first time that patients who switched to Aromasin after Aromasin® Compromises Bone Health in Breast Cancer Patients  -  Jan 31, 2007 Cancer Consultants (press release), However, it was also noted that overall survival is improved with Aromasin. The details of this study appeared in an early online publication on January 27, Aromasin® Compromises Bone Health in Breast Cancer Patients  -  Jan 26, 2007 Cancer Consultants (press release), According to an article recently published in the Lancet, women with breast cancer who switch from tamoxifen (Nolvadex®) to Aromasin® (exemestane) have an New Breast Cancer Survival Data From The Intergroup Exemestane ...  -  Feb 13, 2007 Medical News Today (press release), AROMASIN (exemestane) is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer, Switching Drugs May Help Cancer Patients  -  Feb 15, 2007 WLNS, For example, the study finds that women who switched to Aromasin after two or three years of Tamoxifen improved their condition and chance of living longer. Top Health Stories For Feb. 14, 2007  -  Feb 14, 2007 WOWK, A study found women who switched to Aromasin after two or three years of Tamoxifen improved their condition and their chance of living longer. Breast cancer drug could further reduce mortality  -  Feb 14, 2007 Cancer Research UK - News & Resources, A study published online in the Lancet suggests breast cancer patients who switch drugs from tamoxifen to exemestane (Aromasin) are more likely to survive Switching Breast Cancer Drugs May Boost Survival  -  Feb 14, 2007 WFIE-TV, The researchers looked at the impact of changing from tamoxifen to the aromatase inhibitor exemestane (brand name, Aromasin). UK research claims new breast cancer relapse drug  -  Feb 13, 2007 People's Daily Online, The new drug, sold under the brand name Aromasin, is recommended by the National Institute for Health and Clinical Excellence as an alternative to tamoxifen Ulster cancer victims given wonder drug  -  Feb 13, 2007 Belfast Telegraph, Research has shown that Exemestane or Aromasin is so effective in fighting the disease that it can reduce the risk of dying from breast cancer by 17% New Drug Therapy for Breast Cancer Offers Hope  -  Feb 13, 2007 MedIndia, They are a newer class of drugs and include the medicines Femara, Aromasin, and Arimidex. These fight cancer cell growth in a different way by blocking the As oral cancer drugs gain, dosage problems grow  -  Feb 3, 2007 Boston Globe, Her oncologist eventually convinced her that the benefits of taking the oral hormone therapy Aromasin outweighed the discomfort, but Model had learned Hormone Drug Type Makes Survival Difference In Advanced Breast Cancer  -  Feb 2, 2007 Medical News Today (press release), In addition, aromatase inhibitors -- drugs known as Arimidex, Aromasin and Femara -- are less likely to cause blood clots and vaginal bleeding than other Hormone therapy to treat advanced breast cancer increases survival  -  Jan 31, 2007 South Asian Women's Forum, In addition, aromatase inhibitors — drugs known as Arimidex, Aromasin and Femara — are less likely to cause blood clots and vaginal bleeding than other Hormone drug type makes survival difference in advanced breast cancer  -  Jan 30, 2007 eMaxHealth.com, In addition, aromatase inhibitors - drugs known as Arimidex, Aromasin and Femara - are less likely to cause blood clots and vaginal bleeding than other Hormone drug type shows survival difference in breast cancer  -  Jan 31, 2007 Pharmaceutical Business Review Aromatase inhibitors are drugs such as Arimidex, Aromasin and Femara, which have been available for the past decade or so. The world's largest drug maker to cut 10000 jobs and to close five ...  -  Jan 25, 2007 TopCancerNews.com, A previous announcement has the company -- the maker of cancer drugs Aromasin, Ellence, Camptosar, and Sutent -- slashing costs by $4 billion a year until ASK THE PHARMACIST  -  Jan 23, 2007 Kalamazoo Gazette, ...certain cancers that grow in the presence of estrogen. It is classified as an aromatase inhibitor. Other drugs in this class include Arimidex and Aromasin. Newer drugs beat tamoxifen for breast cancer survival  -  Feb 14, 2007 Asbury Park Press, These medicines, which include Femara, Aromasin and Arimidex, fight cancer cell growth in a different way by blocking the workings of an aromatase enzyme Newer drugs better for breast cancer survival  -  Feb 14, 2007 Bucyrus Telegraph Forum, These medicines, which include Femara, Aromasin, and Arimidex, fight cancer cell growth in a different way by blocking the workings of an aromatase enzyme Newer breast cancer drugs save lives, study finds  -  Feb 13, 2007 CNN ...include anastrozole, made by AstraZeneca Plc under the brand name Arimidex, and exemestane, made by Pfizer Inc. under the brand name Aromasin. New breast cancer drug Exemestane shows great potential to save lives  -  Feb 13, 2007 News-Medical.net, The drug is sold under the brand name Aromasin, and is recommended by the National Institute for Health and Clinical Excellence (NICE) as an alternative to Breast cancer drug 'could save many lives'  -  Feb 13, 2007 Ireland Online, The drug, sold under the brand name Aromasin, is recommended by the National Institute for Health and Clinical Excellence (Nice) as an alternative to New cancer drug to save a thousand lives a year  -  Feb 12, 2007 Times Online, The drug, sold under the brand name Aromasin, is recommended by the National Institute for Health and Clinical Excellence as an alternative to tamoxifen